Gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer:A retrospective study

Case Reports in Oncology

Volumn 3, Issue 3, 2010, Pages 498-504

  Mita, Kazuhito ^a   Ito, Hideto ^a   Fukumoto, Masato ^a   Murabayashi, Ryo ^a   Nabetani, Masashi ^a   Koizumi, Kazuya ^a   Hayashi, Takashi ^a  

^a NEW TOKYO HOSPITAL   (Japan)

Author keywords

Biliary tract cancer; Chemotherapy; Gemcitabine; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; GEMCITABINE;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; DEATH; DEHYDRATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78751532690     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000323560     Document Type: Article

References (16)

1. Patel T: Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002;2:10.
2. Nomura K (ed): Cancer Statistics in Japan 2005. Foundation for Promotion of Cancer Reseach (FPCR), Tokyo, 2005.
3. Glimelius B, Hoffman K, Sjoden PO, et al: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
4. Andrébull;T, Reyes-Vidal JM, Fartoux L, et al: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008;99:862-867.
5. Valle JW, Wasan H, Johnson P, et al: Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - the UK ABC-01 Study. Br J Cancer 2009;101:621-627.
6. Furuse J, Okusaka T, Boku N, et al: S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 2008;62:849-855.
7. Sasaki T, Isayama H, Yashima Y, et al: S-1 monotherapy in patients with advanced biliary tract cancer. Oncology 2009;77:71-74.
8. Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896-902.
9. Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281.
10. Sasaki T, Isayama H, Nakai Y, et al: Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2010;65:1101-1107.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
12. Penz M, Kornek GV, Raderer M, et al: Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001;12:183-186.
13. Knox JJ, Hedley D, Oza A, et al: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005;23:2332-2338.
14. Andrébull;T, Tournigand C, Rosmorduc O, et al: Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004;15:1339-1343.
15. Jarnagin WR, Klimstra DS, Hezel M, et al: Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 2006;24:1152-1160.
16. Gallardo JO, Rubio B, Fodor M, et al: A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001;12:1403-1406.